Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as
therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute